Difference between revisions of "Team:Oxford/Questionnaires"

 
(45 intermediate revisions by 6 users not shown)
Line 1: Line 1:
 
{{:Team:Oxford/Templates/Navi}}
 
{{:Team:Oxford/Templates/Navi}}
 +
 
<html>
 
<html>
<head>
 
<script type="text/javascript">
 
$(document).ready(function(){
 
    $('[data-toggle="popover1"]').popover({placement: "auto"});
 
});
 
</script>
 
<style>
 
  /* Popover Header */
 
  .popover-title {
 
      background-color: #B0C4DE;
 
      color: #FFFFFF;
 
      height: auto;
 
      font-size: 28px;
 
      text-align: center;
 
      padding: 2px;
 
  }
 
  /* Popover Body */
 
  .popover-content {
 
      background-color: ;
 
      color: #000000;
 
      padding: 10px;
 
  }
 
  </style>
 
</head>
 
 
<body>
 
<body>
<script type="text/javascript">
+
 
$(document).ready(function(){
+
<div id="banner" style="background-image: url(https://static.igem.org/mediawiki/2016/thumb/8/84/Surveyyy.png/800px-Surveyyy.png);"></div>
    $('[data-toggle="popover1"]').popover();
+
});
+
</script>
+
<div id="banner" style="background-image: url(https://static.igem.org/mediawiki/2016/b/b9/Collab_header_photo_sam_oxford_2016.jpeg);"></div>
+
  
 
<div class="container-fluid content-main">
 
<div class="container-fluid content-main">
 
<div class="row">
 
<div class="row">
<nav class="col-md-3 bs-docs-sidebar">
+
<nav class="col-md-3 bs-docs-sidebar navFont">
 
         <ul id="sidebar" class="nav nav-stacked" data-spy="affix" data-offset-top="330">
 
         <ul id="sidebar" class="nav nav-stacked" data-spy="affix" data-offset-top="330">
 
             <li>
 
             <li>
                 <a href="#1">Introduction</a>
+
                 <a href="#Intro">Introduction</a>
 
             </li>
 
             </li>
 
             <li>
 
             <li>
                 <a href="#2">First Survey</a>
+
                 <a href="#Suv1">First Survey</a>
 
                         <ul class="nav nav-stacked">
 
                         <ul class="nav nav-stacked">
                        <li><a href="#Standard">Standard</a></li>
+
                          <li><a href="#1q1">Question 1</a></li>
                        <li><a href="#Chelators">Chelators</a></li>
+
                          <li><a href="#1q2">Question 2</a></li>
                        <li><a href="#Other">Other Parts</a></li>
+
                          <li><a href="#1q3">Question 3</a></li>
                </ul>
+
                          <li><a href="#Results1">Results</a></li>
 +
                        </ul>
 
             </li>
 
             </li>
 
             <li>
 
             <li>
                 <a href="#3">Second Survey</a>
+
                 <a href="#Suv2">Second Survey</a>
 
                         <ul class="nav nav-stacked">
 
                         <ul class="nav nav-stacked">
                        <li><a href="#sub1">Question 1</a></li>
+
                          <li><a href="#2q1">Question 1</a></li>
                        <li><a href="#sub2">Question 2</a>
+
                          <li><a href="#2q2">Question 2</a></li>
                        <li><a href="#sub3">Question 3</a>
+
                          <li><a href="#2q3">Question 3</a></li>
                        <li><a href="#sub4">Question 4</a>
+
                          <li><a href="#2q4">Question 4</a></li>
                        <li><a href="#sub5">Question 5</a>
+
                          <li><a href="#2q5">Question 5</a></li>
                        <li><a href="#sub6">Question 6</a>
+
                          <li><a href="#2q6">Question 6</a></li>
                        <li><a href="#sub7">Results</a></li>                        
+
                          <li><a href="#Results2">Results</a></li>
 
+
                        </ul>
                              </ul>
+
             </li><li>
                          </li>
+
                <a href="#Suv3">Third Survey</a>
                        </ul>
+
             </li>
+
            <li>
+
                  <a href="#4">Third Survey</a>
+
 
                         <ul class="nav nav-stacked">
 
                         <ul class="nav nav-stacked">
                        <li><a href="#sub1">Question 1</a></li>
+
                          <li><a href="#3q1">Question 1</a></li>
                        <li><a href="#sub2">Question 2</a>
+
                          <li><a href="#3q2">Question 2</a></li>
                        <li><a href="#sub3">Question 3</a>
+
                          <li><a href="#3q3">Question 3</a></li>
                        <li><a href="#sub4">Question 4</a>
+
                          <li><a href="#3q4">Question 4</a></li>
                        <li><a href="#sub5">Question 5</a>
+
                          <li><a href="#3q5">Question 5</a></li>
                        <li><a href="#sub7">Results</a></li>                                 </ul>
+
                          <li><a href="#Results3">Results</a></li>
             </li>
+
                        </ul>
            <li>
+
             </li><li>
                  <a href="#3">Fourth Survey</a>
+
                <a href="#Suv4">Fourth Survey</a>
 
                         <ul class="nav nav-stacked">
 
                         <ul class="nav nav-stacked">
                        <li><a href="#sub1">Question 1</a></li>
+
                          <li><a href="#4q1">Question 1</a></li>
                        <li><a href="#sub2">Question 2</a>
+
                          <li><a href="#4q2">Question 2</a></li>
                        <li><a href="#sub3">Question 3</a>
+
                          <li><a href="#4q3">Question 3</a></li>
                        <li><a href="#sub4">Question 4</a>
+
                          <li><a href="#4q4">Question 4</a></li>
                        <li><a href="#sub5">Question 5</a>
+
                          <li><a href="#4q5">Question 5</a></li>
                        <li><a href="#sub6">Question 6</a>
+
                          <li><a href="#4q6">Question 6</a></li>
                        <li><a href="#sub7">Question 7</a>
+
                          <li><a href="#4q7">Question 7</a></li>
                        <li><a href="#sub8">Results</a></li>                        
+
                          <li><a href="#Results4">Results</a></li>
 
                         </ul>
 
                         </ul>
</li>
+
            </li>
            </nav>
+
        </ul>
<div class="col-md-9 content-right" style="background-color: #fff;">
+
    </nav>
<h1>QUESTIONNAIRES</h1>
+
 
 +
 
 +
<div class="col-md-9 content-right" style="background-color: #fff;">
  
<section id="1">
+
<div class="pageTitle pageTitlePurple">Surveys</div>
 +
<section id="Intro">
 
<h2>Introduction</h2>
 
<h2>Introduction</h2>
 
<p>
 
<p>
In order to provide a long-term treatment for Wilsons disease we realised we needed to design components of a bacterial system that could detect copper and produce a copper chelators to prevent its absorption by the body. These functions were tested separately to try to get a system able to operate on physiological copper concentrations.
+
Engaging with the public was a key part of our project in order to ensure that the results of the project were of benefit and acceptable to all. In order to do this we carried out surveys with members of the public at strategic points to guide the project in the best direction.
 
</p>
 
</p>
 +
</section>
 +
 +
<section id="Suv1">
 +
<h2>First Survey</h2>
 
<p>
 
<p>
Throughout all of our experiments we tried to think about whether the conditions the bacteria were growing in were likely to be realistic of the gut environment.  
+
We carried out our first survey before Christmas to investigate the issues people would like to be addressed by an interdisciplinary science project. When combined with our teams skills this guided the overall direction of our project down the iGEM therapeutic track.
 
</p>
 
</p>
 +
<section id="1q1">
 +
<h3>Do you think that synthetic biology can contribute towards the solution of serious global challenges?</h3>
 
<p>
 
<p>
We spoke to patients with Wilsons’s disease and realised that, whilst many were comfortable with the idea of a synthetic biology treatment, the administration method for the treatment was one of their priorities. Many complained that their current treatments involved pills that were too large, had to be taken too frequently and had to be kept refrigerated making travelling difficult. From their feedback we investigated small alginate beads layered to survive the stomach in order to deliver our probiotic and hopefully found a large enough started population to have persistence in the gut.
+
All of our respondents thought that synthetic biology could contribute to serious global challenges which reassured us that the outcome of our synthetic biology project would be useful, and that this is an area of science that the public have faith in.
 
</p>
 
</p>
 
 
</section>
 
</section>
 
+
<section id="1q2">
<section id="2">
+
<h3>What area would you like a project of this sort to focus on?</h3>
<h2>Survey 1</h2>
+
</p>
+
In this survey we aimed to: investigate the public’s awareness of scientific issues that arise from our project to establish the areas we need to focus on in our outreach activities,
+
assess the level of support our project might have if it were to be used as a treatment in the future and get an initial idea of whether people would prefer a single treatment or daily pill.
+
<p>
+
<section id="Question 1">
+
<h3>How old are you?</h3>
+
 
<p>
 
<p>
We found we had an uneven spread of age groups with a heavy bias towards under 21s. This is probably because we shared our survey shared via Facebook which has lots of younger users particularly among our friends who we got to fill it in. A a lot of our friends under 21 are those doing biology related degrees like us at university so they may not be representative of their age group as a whole. This may impact on results as different age groups learn different things at school according to age and people’s opinions on medical treatments may vary with age as issues become prominent. We decided to split results into under 21 and over 21 as the older groups are much smaller so there is little point in distinguishing between them.
+
We found that the majority of people questioned favoured medical treatments as their preferred area of research. This question was a free answer although the question prompted some answers: "For example: diagnostics, energy, environment, food and nutrition, information processing, manufacturing, therapeutics etc." This may have had an impact on what people chose, but out of the different iGEM tracks available medical and therapeutic purposes were the most preferred.  
 
</p>
 
</p>
</p>
+
<img src="https://static.igem.org/mediawiki/2016/9/99/T--Oxford--1.1.jpg">  
 
</section>
 
</section>
<section id="Question 2">
+
<section id="1q3">
<h3>Had you heard of genetic engineering before this survey?/h3>
+
<h3>What specific problem would you like to have solved by an interdisciplinary, synthetic biology-based project?</h3>
 
<p>
 
<p>
  We found that 90% people have heard of genetic engineering so don’t need to focus too much on public awareness of this
+
This was a unprompted, free answer question and gave us answers such as Malaria, treatment of the common cold and asthma treatment. Many were quite vague and not feasible for us to solve in one summer, but one person suggested probiotic supplements which got us interested in using probiotics as a treatment for diseases in general.
Awareness greater among younger people than older people so if anything we should be focusing on people over 21 but 90% overall means we probably don’t need to do this.
+
 
</p>
 
</p>
 
</section>
 
</section>
<section id="Other">
+
<section id="Results1">
<h3>Other Parts</h3>
+
<h3>Results</h3>
 
<p>
 
<p>
One of our promoter parts (pCopA sfGFP with constitutive sfGFP) was sequenced four times from separate PCR and transformation attempts and had the same two point mutations on each attempt. We attributed this to a synthesis issue and this part was abandoned.  However we wanted to get a similar sequence with the same design as this part so we amplified the promoter system and constitutive CueR only from our part: pCopA MymT sfGFP with constitutative CueR and then ligated the resulting sequence with prefix and suffix into the pSB1C3 shipping vector.
+
This survey was designed to give us some idea as to the direction our project should take. Based on this we decided to investigate the use of bacteria as a medical treatment.
</p>
+
<p>
+
We also received from Tom Folliard, a PhD student in our lab, a plasmid containing a copper biosensor (pCusC mKate) he had done a small amount of work on previously. We characterised this part further and attempted to make it biobrick compatible. As the part had an illegal <a data-toggle="popover1" data-trigger="hover" title="SpeI" data-content="A/CTAGT" placement: "top">SpeI</a> restriction site in the ribosome-binding site we amplified the promoter region only so we could deposit this in the registry. We also wanted to deposit the entire testing component complete with promoter, ribosome binding site and RFP. After attempts at site directed mutagenesis failed we ordered this part without this site from IDT.
+
 
</p>
 
</p>
 
</section>
 
</section>
 
</section>
 
</section>
  
<section id="3">
+
<section id="Suv2">
<h2>Promoter Characterisation</h2>
+
<h2>Second Survey</h2>
<section id="sub1">
+
<h3>Experimental Design</h3>
+
 
<p>
 
<p>
We decided that our copper chelating bacteria would require a promoter system able to detect dietary copper rather than just constitutive expression. This has three main advantages:
+
In this survey we aimed to investigate the public’s awareness of scientific issues that arise from our project to establish the areas we need to focus on in our outreach activities, assess the level of support our project might have if it were to be used as a treatment in the future and to get an initial idea of whether people would prefer a single or repetaed treatment plan which effected the designs of our genetic circuit.
 
</p>
 
</p>
<li>
+
<section id="2q1">
If the bacteria are made to produce the chelator constantly, even when it is not required, then this will increase use of cell resources such as amino acids. This increases selection pressure for the gene to mutate out and decreases the likelihood of our bacteria strain being able to successfully compete with other gut bacteria.
+
<h3>How old are you?</h3>
</li>
+
<li> If the copper chelator is expressed at all times then the rate of copper chelation is essentially uncontrolled and only a function of the number of bacteria present which could could feasibly vary slightly due to short-term factors such as food intake or illness. This unpredictable behaviour would be difficult to reconcile with other treatments.
+
</li>
+
<li>
+
Constitutive chelator expression that is too low for a particular patent at a particular time will not treat their symptoms effectively. If the chelator expression is too high however they may experience copper deficiency. </li>
+
 
<p>
 
<p>
We found two different copper sensitive promoter systems: CueR-linked and CusS/CusR-linked (see our <a href="https://2016.igem.org/Team:Oxford/Parts#Promoters">parts page</a>) and investigated rearranging the components to form feedback systems in order to improve sensitivity over the physiological range of copper concentrations.  
+
We found that we had an uneven spread of age groups  among our respondents with a heavy bias towards under 21s. This is probably because the survey was shared via Facebook which has a lot of younger users, and shared particularly among our friends who we requested fill it in. In addition a lot of our friends aged under 21 are doing biology-related degrees at university so their knowledge may not be representative of their age group as a whole. We decided to split the results into under 21 and over 21 as the older groups were so sparsely populated there was little advantage in distinguishing between them.
 
</p>
 
</p>
 +
<img src="https://static.igem.org/mediawiki/2016/b/b3/T--Oxford--2.1.jpg">
 +
</section>
 +
<section id="2q2">
 +
<h3>Had you heard of genetic engineering before this survey?</h3>
 
<p>
 
<p>
We aimed to characterise all of our promoters using three different methods:
+
We found that 90% people surveyed have heard of genetic engineering before this survey and we concluded that informing about genetic engineering shouldn't be our priority in our outreach activities.
 
</p>
 
</p>
<li>
+
<img src="https://static.igem.org/mediawiki/2016/a/a1/T--Oxford--2.2.jpg">
Plate reader
+
</section>
</li>
+
<section id="2q3">
<li>
+
<h3>Had you heard of synthetic biology before this questionnaire?</h3>
Flow cytometry
+
</li>
+
<li>
+
Microscopy
+
</li>
+
 
<p>
 
<p>
The plate reader experiments were preformed to study how the expression of the fluorescent protein changes with copper concentration and changes over time. This data was used to parameter fit the models of each promoter system.  
+
Only a small majority overall have heard of synthetic biology so we concluded it would be worth performing some outreach projects to make people more aware of synthetic biology so they can be more informed and engaged in our project. A majority of older people had not heard of synthetic biology before so ideally it this is the age group where we would be focussing our efforts. We concluded that we should target our outreach to more established forms of communication such as radio rather than focusing on just social media which has a much younger demographic.
 
</p>
 
</p>
 +
<img src="https://static.igem.org/mediawiki/2016/e/e4/T--Oxford--2.3.jpg">
 +
</section>
 +
<section id="2q4">
 +
<h3>Have you heard of Orphan Diseases (e.g. Wilson’s Disease)?</h3>
 
<p>
 
<p>
Flow cytometry was performed to confirm the results of the plate reader and to provide a measure of the variance in expression within each population at different copper concentrations.
+
Our results showed that Orphan diseases need greater awareness as most people haven’t heard of them. When awareness of rare disease is low amongst both the public and medical professionals, patients of these diseases are less likely to get a correct diagnosis. Public awareness also affects the research allocation to rare diseases which are often underfunded.
 
</p>
 
</p>
 +
<img src="https://static.igem.org/mediawiki/2016/f/fc/T--Oxford--2.4.jpg">
 +
</section>
 +
<section id="2q5">
 +
<h3>If your doctor recommended the use of genetically engineered bacteria to treat an illness, would you use it?</h3>
 
<p>
 
<p>
Microscopy was performed to qualitatively confirm the results of the previuos two methods and to study the cellular localisation of the fluorescent proteins.
+
Already a majority of people said they would use a genetically engineered bacteria as a treatment and a third of people didn’t know. If they were given more information about the treatment they might be persuaded to accept it so we should aim to do inform about the nature of our bacteria as we work on our project. Is the decision to take a treatment largely due to a doctor's recommendation or are other people making the decision for themselves from their own knowledge of synthetic biology? We found that a larger proportion of younger people prepared to take a probiotic treatment and previously a greater number of these people had heard of genetic engineering, suggesting this decision is linked to knowledge levels. this does not however account for the fact that attitudes to medical advice varies between age groups.
 
</p>
 
</p>
 +
<img src="https://static.igem.org/mediawiki/2016/a/a0/T--Oxford--2.5.jpg">
 +
</section>
 +
<section id="2q6">
 +
<h3>If you were given the option between taking a daily pill for an extended period of time, or a single probiotic bacterial pill to treat an illness, which would you choose?</h3>
 
<p>
 
<p>
Further details of each of these can be found on our <a href="https://2016.igem.org/Team:Oxford/Experiments">experiments page</a> and full protocols on our <a href="https://2016.igem.org/Team:Oxford/Protocols">protocols page</a>.
+
A single pill is preferable to a daily pill for the majority of respondents, however our results show that most people would follow their doctor’s recommendation. This suggests in previous question that many of the responses in favour of such a treatment are in large part guided by the doctor's recommendation. We could do another survey to clarify this by repeating the question without giving them the option of allowing a doctor to choose for them. This question highlights how important it is to inform doctors not just patients of our treatment as their input would be required to make our treatment widely acceptable. We decided that we should discuss our treatment with doctors to get their opinions and work out what we would have to do to convince them that our probiotic is safe.  
 
</p>
 
</p>
</section>  
+
<img src="https://static.igem.org/mediawiki/2016/f/f1/T--Oxford--julia-2.6new.png"/>
 
+
</section>
<section id="sub2">
+
<section id="Results2">
 
<h3>Results</h3>
 
<h3>Results</h3>
 
<p>
 
<p>
For all of our promoter systems the results of all three experimental methods were broadly consistent.  
+
In conclusion, the majority of people have heard of genetic engineering and synthetic biology. If we were to raise awareness of these issues then we should focus on older people rather than younger people, although there is benefit in talking to as many people as possible. Most people have not heard of orphan diseases so raising awareness of these should be a priority and we will try to do this. We found that people were wiling to follow what their doctors recommended so we should ensure that doctors are informed of our treatments, rather than just focusing on the view of patients. We should do another survey to clarify whether a single or daily dose is preferable, and maybe remove the reference to doctor's recommendation as this might be influencing people’s responses.
 
</p>
 
</p>
 +
</section>
 +
</section>
 +
 +
<section id="Suv3">
 +
<h2>Third Survey</h2>
 
<p>
 
<p>
We investigated three designs of a promoter system based upon the CueR-linked system:
+
This survey was designed to investigate the ethical issues people might have with our project so we can respond to these and try and minimise these concerns through the design of project or generate counter arguments.
 
</p>
 
</p>
 +
<section id="3q1">
 +
<h3>How old are you?</h3>
 
<p>
 
<p>
One (pCopA sfGFP) was the simplest but only responsive to copper at high concentrations. This promoter alone was therefore not considered suitable for our system.
+
This time we had fewer responses than before and some groups have no people in them at all. Therefore we will split responses into under and over 21 like before. We think the reasons for this age spread are the same as those seen in survey 1 but older groups are even less represented in this survey because there are fewer responses overall.
 
</p>
 
</p>
 +
<img src="https://static.igem.org/mediawiki/2016/e/e1/T--Oxford--3.1.jpg">
 
</section>
 
</section>
<section id="subA">
+
<section id="3q2">
<p><b>pCopA sfGFP</b></p>
+
<h3>Do you understand the term 'genetically-engineered bacteria'?</h3>
<img src="https://static.igem.org/mediawiki/2016/f/fd/Pcg_graph_4h_sam_oxford_2016.jpeg" width="50%" />
+
<img src=" https://static.igem.org/mediawiki/2016/0/04/Pcg_flow_cyto_diagram_oxford_sam_2016.jpeg" width="50%" />
+
<img src=" https://static.igem.org/mediawiki/2016/d/df/Pcg_microscopy_picture_results_oxford_sam_2016.jpeg" width="50%" />
+
</section>
+
 
+
<section id="subB">
+
 
<p>
 
<p>
To investigate whether this insensitivity was due to there being only a single copy of the CueR gene from the cell genome compared with the 500+ copies of pCopA on the high copy plasmid we wanted to test a version of the part with constitutive CueR. We based this upon a part in the registry already (see our <a href="https://2016.igem.org/Team:Oxford/Parts#Promoters">parts page</a>) but never managed to clone it successfully possibly due to a synthesis issue. However we did produce two parts (Numbers) with our chelators in front of the sfGFP. These are expected to operate much like the part without the chelator if we consider the amount of copper bound by the chelator to be negligible. These both appeared more copper responsive than the pCopA promoter alone although the much large TAT Csp1 appeared to have expression issues at higher copper concentrations forming inclusion bodies seen in the microscopy images: </p>
+
We covered this topic in the previous survey and received more responses in that. We will not analyse the data from this question therefore due to the smaller sample size.
<p><b>pCopA MymT sfGFP with constitutive CueR</b></p>
+
</p>
<img src="https://static.igem.org/mediawiki/2016/4/42/Pmg_4h_graph_sam_oxofrd_2016.jpeg" width="50%" />
+
<img src="https://static.igem.org/mediawiki/2016/7/74/Pmg_flow_cyto_oxford_sam_2016.jpeg" width="50%" />
+
<img src="https://static.igem.org/mediawiki/2016/c/c8/Pmg_microscopy_together_sam_oxford_2016.jpeg" width="50%" />
+
<p><b>pCopA TAT Csp1 sfGFP with constitutive CueR</b></p>
+
<img src="https://static.igem.org/mediawiki/2016/9/97/Ptcg_graph_4h_sam_oxford_2016.jpeg" width="50%" />
+
<img src="https://static.igem.org/mediawiki/2016/0/0d/Ptcg_flow_cyto_sam_oxford_2016.jpeg" width="50%" />
+
<img src="https://static.igem.org/mediawiki/2016/a/a8/Ptcg_microscopy_oxford_sam_2016.jpeg" width="50%" />
+
</section>
+
 
+
<section id="subC">
+
<p>We wanted to experiment with the CueR-system further by adding in a feedback loop. CueR has an interesting mechanism of action meaning that it can operate both as an activator and a repressor depending on the copper concentration. We designed a part where CueR is expressed from pCopA from a plasmid in front of sfGFP hoping that this would act as a positive feedback system increasing the sensitivity of the part. Instead it appears to act as negative feedback system dampening the response to copper compared to the part with constitutive expression.  This also seems to have reduced the variation between cells as shown by the flow cytometer data. Under some circumstances this could be a useful feature being able to keep the chelator concentration more similar and predictable over a wider concentration range but this part and behaviour was not deemed to be useful over the physiological copper concentrations we were interested in.</p>
+
<p><b>pCopA CueR sfGFP/ Feedback pCopA sfGFP</b></p>
+
<img src="https://static.igem.org/mediawiki/2016/9/99/Fcg_4h_graph_sam_oxford_2016.jpeg" width="50%" /><img src="https://static.igem.org/mediawiki/2016/7/73/Fcg_flow_cyto_sam_oxford_2016.jpeg" width="50%" />
+
<img src="https://static.igem.org/mediawiki/2016/8/8d/Fcg_microscopy_sam_oxford_2016.jpeg" width="50%" />
+
 
</section>
 
</section>
 
+
<section id="3q3">
<section id="subD">
+
<h3>If your doctor recommended the use of genetically-engineered bacteria to treat an illness, would you use it?</h3>
<p>We also received a part containing a copper biosensor: pCusC mKate, from Tom Folliard, a PhD student in our lab. Whilst he had some preliminary late reader data we characterised it further. While not directly comparable to our other parts due to the different fluorescent protein this promoter turned out to be much more sensitive and responsive than any of the CueR systems:  </p>
+
<p>
<p><b>pCusC mKate</b></p>
+
Again this question was better covered in the previous survey.
<img src="https://static.igem.org/mediawiki/2016/9/92/PCusC_RFP_4h_graph_Oxford_Sam_2016.jpeg" width="50%" />
+
</p>
<img src="https://static.igem.org/mediawiki/2016/9/90/PCusC_flow_cyto_sam_oxford_2016.jpeg" width="50%" />
+
<img src="https://static.igem.org/mediawiki/2016/9/97/PCusC_microscopy_sam_oxford_2016.jpeg" width="50%" />
+
 
</section>
 
</section>
 
+
<section id="3q4">
+
<h3>What do you think people's concerns are about the use of genetically-engineered bacteria (e.g., releasing genetically engineered bacteria into the environment, safety for the patient, "playing God", unjust or unnatural etc.)?</h3>
</section>
+
<p>
 
+
Issues related to safety (bottom four) were most important to people. We should combat this by focusing our research efforts on ways to stop our bacteria surviving outside the body and way to stop the treatment if it was having undesired affects. There were considered in our safety flowchart.
<section id="4">
+
Unknown long term effects are a concern to people so we should aim to minimise the use of risky techniques and educate people about the benefits this technology can provide in addition to allowing balanced discussion of the possible risks the technology could create. The same attitude applies for the concerns about God and unnatural methods. We should acknowledge that these are problems where people have legitimate fears and concerns and we should approach these concerns carefully and not dismiss them while bringing in a broader discussion on the potential benefits of synthetic biology.</p>
<h2>Copper Chelation</h2>
+
<p>
<p>We attempted to show that our two copper chelating proteins chelated copper when expressed from<i> E. coli.</i> With limited time and budget we tried to develop a absorbance assay for copper using the reagent BCS. (1)(2) We used this to assay to test both live cells and purified proteins for the ability to reduce free copper concentration. Unfortunately the assay was either too insensitive to show an effect or our chelators were not operating as intended. With more time we hoped to develop the assay further.</p>
+
The statements given as examples tended to be popular but we had no way of telling whether they would have been popular if unprompted – we should possibly have made this question a free, unprompted choice as we believe the question could still be understood without prompts.
<p>We also came across a paper by  Hötzer et al (3) that detailed how it might be possible to use the fluorescence lifetime of a His tagged GFP as a copper assay. Lacking access to a FLIM machine we contacted Cardiff iGEM who were kind enough to run a few of our samples in their FLIM machine.</p>
+
The number of responses for each point is dependent on how general the categories are, as we couldn't get the subtleties of individual answers onto a chart we had to group them together rather broadly to see which issues are the most pressing which involves making very subjective decisions in the interpretation of answers.
<section id="BCS">
+
</p>
<h3>BCS Absorbance Assay</h3>
+
<img src="https://static.igem.org/mediawiki/2016/b/bd/T--Oxford--3.4.jpg">
<p> Description of how the assay works.</p>
+
<section id="in vivo">
+
<h3>Assay <i>in vivo</i></h3>
+
<p> Description of how we tested in vivo.</p>
+
<p> Description of how we tested in vivo.</p>
+
<p> Description of how we tested in vivo.</p>
+
<p> Description of how we tested in vivo.</p>
+
<p> Description of how we tested in vivo.</p>
+
 
</section>
 
</section>
<section id="purification">
+
<section id="3q5">
<h3>Protein Purification</h3>
+
<h3>Why would you (or why do you think other people would) be against the use of these bacteria in a medical treatment?</h3>
<p>How Andreas purified shit</p>
+
<p>
<p>How Andreas purified shit</p>
+
Bacteria are perceived as pathogens so using them as a medical treatment seems counter-intuitive and people are not comfortable with willingly exposing themselves to bacteria. There is a sense that people are misinformed about GMOs and bacteria, so with more education both of these problems could be addressed.  We will do this via our summer schools and social media presence. Unknown consequences and the lack of previous success are also issues. We could argue that we can only find the answers to these questions by investigating the treatment, or that the potential benefits of our project should outweigh the theoretical, unspecified disadvantages. There are still environmental and safety concerns, but the ethical and religious issues don’t seem to apply here, perhaps because this is specified as a medical treatment. If we think this is the case we should really emphasise the medical application of this technology, and specifically our project, if we want to ensure the widest support for what we’re doing.
<p>How Andreas purified shit</p>
+
</p>
<p>How Andreas purified shit</p>
+
<img src="https://static.igem.org/mediawiki/2016/6/64/T--Oxford--3.5.jpg">
<p>How Andreas purified shit</p>
+
 
</section>
 
</section>
<section id="in vitro">
+
<section id="Results3">
<h3>in vitro</h3>
+
<h3>Results</h3>
<p> Description of how we tested in vitro.</p>
+
<p>
<p> Description of how we tested in vitro.</p>
+
This survey shows us that we need to consider safety – all aspects of safety including environmental, patient and mutation risk safety. This is addressed in our safety flow chart.
<p> Description of how we tested in vitro.</p>
+
Unknown consequences should be considered, and although there will always be the possibility of these occurring we can take steps to minimise them and emphasise how the benefits of the treatment should outweigh them if implemented carefully. This is the same for unnatural and religious based arguments, we should acknowledge that these are potential issues and address them. However these views were not as widely held as we expected. To get people to be in favour of using bacteria as a medical treatment we will have to work hard to convince people that bacteria can be safe and useful rather than just a pathogen.
<p> Description of how we tested in vitro.</p>
+
</p>
<p> Description of how we tested in vitro.</p>
+
<p> Description of how we tested in vitro.</p>
+
 
</section>
 
</section>
 
</section>
 
</section>
<section id="FLIM">
+
 
<h3>Fluorescence Lifetime Imaging</h3>
+
<section id="Suv4">
<p>Text about the Cardiff Collaboration. with lots of thanks to go around.</p>
+
<h2>Fourth Survey</h2>
 +
<p>
 +
This survey was designed to investigate the preferred delivery methods for our treatment and the dosage frequency people would tolerate. This information was used to decide how to deliver our probiotic and to clarify whether people would prefer a permanent population in the small intestine or more frequent applications. This survey was performed in collaboration with iGEM Vilnius so that we can compare the results between the two different countries and see how opinions differ internationally.
 +
</p>
 +
<section id="4q1">
 +
<h3>Are you a Wilson's Disease patient?</h3>
 +
<p>
 +
We added this question about Wilson’s disease after we made the survey but before posting it on the Wilson’s Disease Support group Facebook page. We will assume that the people who didn’t answer this question do not have Wilson’s disease as the chance of someone with Wilson’s disease finding the survey and filling it in are very small. 21 respondents had Wilson’s disease, 16 respondents definitely did not and 40 respondents answered before we added this question but we assume they did not have Wilson’s disease either, making 56 overall.
 +
Vilnius did not ask this as they are working on phenylketonuria rather than Wilson’s disease.
 +
</p>
 +
<img src="https://static.igem.org/mediawiki/2016/b/bc/T--Oxford--4.1.jpg">
 
</section>
 
</section>
<h3>References</h3>
+
<section id="4q2">
 +
<h3>Have you ever taken a probiotic treatment and, if so, did it have any effect?</h3>
 
<p>
 
<p>
(1) Poillon W. and Dawson C. (1963)"ON THE NATURE OF COPPER IN ASCORBATE OXIDASE I. THE VALENCE STATE OF COPPER IN THE DENATURED AND NATIVE ENZYME"
+
In the UK the proportion of people who hadn’t tried a probiotic treatment was greater than those who had; in Lithuania the opposite is true. We believe these sort of treatments are more common in Lithuania that in the UK. Although we explained what a probiotic is this lack of familiarity may have stopped UK respondents recognising that this applies to food products.
Biochim Biophys Acta. 1963 Sep 3;77:27-36
+
Of those who had tried a probiotic treatment, in all the large groups, more people said that they had no effect on their health than a positive effect, suggesting many people would be sceptical of using probiotics as a medical treatment. If the project were to be taken forward we would want to peform marketing to improve the image of probiotics so people would be more willing to take them.
 
</p>
 
</p>
 +
<img src="https://static.igem.org/mediawiki/2016/c/c2/T--Oxford--4.2.jpg">
 +
</section>
 +
<section id="4q3">
 +
<h3>In general, how would you prefer to take a probiotic treatment?</h3>
 
<p>
 
<p>
(2) Rapisarda V., Volentini S., Ricardo N., Massa E. (2002) "Quenching of bathocuproine disulfonate fluorescence by Cu(I) as a basis for copper quantification" Analytical Biochemistry, 307(1)m pp. 105-109. doi: 10.1016/S0003-2697(02)00031-3
+
Consumable products are less popular in all groups than pharmaceutical products which suggests this is how we should plan to deliver our treatment. This is convenient because we can’t make food in our lab, controlling the dose is easier and people won’t get bored of having to take a certain type of food repeatedly and decline to take it. Pharmaceutical products may be more trusted or deemed more appropriate for treating a serious condition. Higher proportion of people in Lithuania would take the consumable product than the UK which we think is due to these sorts of products being more widespread in Lithuania. We discussed this with the team in Vilnius.
 
</p>
 
</p>
 +
<img src="https://static.igem.org/mediawiki/2016/4/47/T--Oxford--4.3.jpg">
 +
</section>
 +
<section id="4q4">
 +
<h3>Of the options listed below, which would be your preferred pharmaceutical delivery method?</h3>
 
<p>
 
<p>
(3) Hötzer B., Ivanov R., Altmeier S., Kappl R., Jung G., (2011) "Determination of copper(II) ion concentration by lifetime measurements of green fluorescent protein."  Journal of Fluorescence, 21(6), pp. 2143-2153. doi: 10.1007/s10895-011-0916-1
+
The UK results show that a gel-like bead or a tablet/pill are the most popular options. We decided to research a gel-like bead as this builds on work done by previous Oxford iGEM teams. Results from both countries show tablet or pill is the most popular but these are also the most familiar. It’s likely that people did’t really know what a gel-like bead would be meaning that we should inform them of this when explaining our project.  
 
</p>
 
</p>
 +
<img src="https://static.igem.org/mediawiki/2016/d/d3/T--Oxford--4.4.jpg">
 
</section>
 
</section>
 
+
<section id="4q5">
<section id="5">
+
<h3>Would you prefer to take a probiotic treatment regularly or a single treatment that creates a permanent population of bacteria in the gut (meaning that no further treatment would be required)?</h3>
<h2>Alginate Bead Preparation</h2>
+
<p>Based upon patient feedback into delivery systems we decided to investigate the feasibility of using <a data-toggle="popover1" data-trigger="hover" title="Alginate" data-content="An anionic polysaccharide produced by brown algae" placement: "top">alginate</a> beads to encase our bacteria and successfully deliver them to the intestine, while maintaining their integrity in the stomach. As quantitative measure of bead stability we used the dye <a href="https://2016.igem.org/Team:Oxford/Chemicals">Crystal Violet</a> which we could measure by it absorbance at 495nm.</p>
+
<section id="alginate">
+
<h3>Alginate only</h3>
+
<p>Our first experiment was to prepare a 2% (weight/volume) sodium alginate solution, which was done dissolving 2g of alginate in 100ml of warm MilliQ. We then added 2ml of the dye. This solution was then dropped with a pipette into a solution of 0.1mM CaCl<sub>2</sub> that solidifies and hardens the alginate. </p>
+
 
<p>
 
<p>
We found during their first 30 minutes in the CaCl<sub>2</sub> solution (the “stabilisation phase”) dye did leak from the beads. We then transferred the beads into a fresh CaCl<sub>2</sub> solution and found the beads no longer leaked dye. Hence, the beads had stabilised.
+
The majority of people want a single treatment so if this were feasible we should try to develop this. This could reduce the problems with storing the pills or beads as they would only need to be taken once so would not need to be stored in the home. We would need to ensure however that our bacteria could compete and survive in the human intestine otherwise a single treatment would be ineffective. We would need a control mechanism to kill the bacteria once they are outside the body regardless of whether it is a single or a regular treatment.
 
</p>
 
</p>
<p>The beads before hardening showing leakage of the dye:</p>
+
<img src="https://static.igem.org/mediawiki/2016/d/d9/T--Oxford--4.5.jpg">
<img src="https://static.igem.org/mediawiki/2016/0/0c/Beads_before_hardening_sam_oxford_2016.png" width="50%" />
+
<p>The beads after hardening in one calcium solution for 30mins then transferred to another for one hour with no signs of leakage:</p>
+
<img src="https://static.igem.org/mediawiki/2016/a/ad/Beads_after_sam_oxford_2016.png" width="50%" />
+
 
+
<p> To investigate the stability of our beads within the body we decided to place the alginate-dye beads into stomach and intestine simulation solutions and measured the concentration of dye released into each solution using absorbance at 595nm.</p>
+
<li>We stimulated the conditions of the stomach by making up 0.2% (w/v) NaCl solution made up to pH 2.0 with 1M HCl. </li>
+
<li>We simulated the conditions of the intestine by making 0.68% (w/v) monobasic potassium phosphate solution, made up to pH 7.2 with 1M NaOH. </li>
+
<p>The 2 solutions are placed into a incubator shaking at 37&#176;C for 90 minutes. Every 10 minutes 100μl of solution is removed and placed into 1 well of a 96 well plate. Measure absorption of each well once 90 minutes is complete. </p>
+
<p>GRAPH HERE WHEN DONE</p>
+
<p>The results suggested alginate beads would not be able to carry out bacteria successfully into the intestine, as the stomach acid would disintegrate the beads and hence kill our bacteria. We then decided to re-design the beads.</p>
+
 
</section>
 
</section>
<section id="Chitosan">
+
<section id="4q6">
<h3>With Chitosan</h3>
+
<h3>Ideally, how often would you prefer to take a probiotic treatment? (Select all that apply.)</h3>
<img src="https://static.igem.org/mediawiki/2016/3/34/Alginate_chitosan_sam_oxford_2016.png" width="50%" />
+
<p>
<p>Upon analysis of our results we decided to improve the stability of the beads using repeating layers of <a data-toggle="popover1" data-trigger="hover" title="Chitosan" data-content="A linear polymer of glucosamine and N-acetyl-glucosamine sugar units made by alkali digestion of shrimp shells" placement: "top">chitosan</a> and alginate. This was suggested by our research into probiotic delivery. The layering was done by preparing the beads as before then after their 30 minutes hardening, filtering them and alternatively dipping into 0.4% (w/v) chitosan solution (in 0.1M acetic acid adjusted to pH 6.0 with 1M NaOH, 10ml) for 10 mins and 0.04% (w/v) alginate solution (10ml) for 10 min.</p>
+
Overall slightly more people would prefer to take the pill once a day than once ever, but Wilson’s patients are more likely to want a pill once ever than once a day. As these are people who know what it’s like to take a pill every day and would benefit most from our treatment this is another reason to develop a more long lasting treatment. This complements a question in the second survey we performed, in which we found that the majority of people who expressed a preference would prefer to take a single pill than a pill once a day.
<p>10ml of these beads were placed in flasks of 100ml stomach simulate and intestinal simulate solutions and incubated in a 37&#176;C shaker for 90 minutes. Every 10 minutes, 100μl samples were taken and after the whole 90 minutes the absorbance of each of the samples was measure at 595nm with a plate reader. </p>
+
<p>GRAPH HERE WHEN DONE</p>
+
<p>We found that our the absorbance of the stomach solution did not increase over time indicating that layering the alginate with chitosan allowed the beads to maintain their structural integrity and retain the dye. Conversely, in the small intestine, the more alkaline pH causes the layered coating to degrade, steadily releasing dye into solution. </p>
+
<p>This suggests that this method would be a good way of delivering our bacteria to the small intestine, as our probiotic would be released along the small intestine.</p>
+
<p>If we had more time we would test this system again by encapsulating bacteria that constitutively express GFP into the original alginate matrix and measure the fluorescence at different time points. At the end of the experiment, test the viability of the bacteria by taking an aliquot of the small intestine solution and adding it to LB broth and leaving to incubate overnight. Bacterial growth would show the bacteria had survived the solution.</p>
+
<h3>References</h3>
+
<p>Cook, M.T., Tzortzis, G., Khutoryanskiy, V.V. and Charalampopoulos, D. (2013) ‘Layer-by-layer coating of alginate matrices with chitosan–alginate for the improved survival and targeted delivery of probiotic bacteria after oral administration’, J. Mater. Chem. B, 1(1), pp. 52–60. doi: 10.1039/c2tb00126h.
+
 
</p>
 
</p>
 +
<img src="https://static.igem.org/mediawiki/2016/7/70/T--Oxford--4.6.jpg">
 +
</section>
 +
<section id="4q7">
 +
<h3>If this were not possible, how often would you be prepared to take a probiotic treatment? (Select all that apply.)</h3>
 
<p>
 
<p>
Chávarri, M., Marañón, I., Ares, R., Ibáñez, F.C., Marzo, F. and Villarán, M. del C. (2010) ‘Microencapsulation of a probiotic and prebiotic in alginate-chitosan capsules improves survival in simulated gastro-intestinal conditions’, International Journal of Food Microbiology, 142(1-2), pp. 185–189. doi: 10.1016/j.ijfoodmicro.2010.06.022.
+
A daily pill appears to be acceptable to most people, so if we were unable to make a sustainable probiotic population, this would be an alternative we should investigate. People would be prepared to take it more than once a day if necessary so we if we found that the amount of bacteria we need to turnover is too high to take just once a day, our probiotic would still be acceptable if taken more frequently. Ideally we would like to create a population with some ability to persist so that our treatment is improved, at least in regards to dosage frequency, over the existing treatments for Wilson’s disease which have to be taken multiple times a day.  
 
</p>
 
</p>
 +
<img src="https://static.igem.org/mediawiki/2016/a/a1/T--Oxford--4.7.jpg">
 +
</section>
 +
<section id="Results4">
 +
<h3>Results</h3>
 
<p>
 
<p>
Krasaekoopt, W., Bhandari, B. and Deeth, H. (2004) ‘The influence of coating materials on some properties of alginate beads and survivability of microencapsulated probiotic bacteria’, International Dairy Journal, 14(8), pp. 737–743. doi: 10.1016/j.idairyj.2004.01.004.
+
From this survey we have found that probiotic treatments are not widely taken in the UK but results from Lithuania suggest they may be more common in other countries. We might need to raise more awareness of them if we were to develop this into an actual product rather than a proof of concept. We should investigate a pharmaceutical delivery method rather than a consumable product delivery method. We decided to investigate delivery via a gel-like bead because this was one of the most popular options in the UK and it is feasible for us to achieve. A single treatment is more popular than a regular treatment. If we were to re-run this survey in the future we should prevent people from giving more than one answer as this makes the results very hard to interpret. If necessary people would be willing take a pill once a day, so if we find we couldn't make a population that persist in the small intestine, our probiotic may still have value.
 
</p>
 
</p>
 
 
</section>
 
</section>
 
</section>
 
</section>
<section id="6">
 
  
<h2>Conclusions</h2>
 
<p>How did we do in all three areas and what experiments would we do if we had more time, energy and money</p>
 
<p>How did we do in all three areas and what experiments would we do if we had more time, energy and money</p>
 
<p>How did we do in all three areas and what experiments would we do if we had more time, energy and money</p>
 
<p>How did we do in all three areas and what experiments would we do if we had more time, energy and money</p>
 
<p>How did we do in all three areas and what experiments would we do if we had more time, energy and money</p>
 
</section>
 
</div>
 
 
</div>
 
</div>
 
</div>
 
</div>

Latest revision as of 22:14, 19 October 2016

iGEM Oxford 2016 - Cure for Copper

Surveys

Introduction

Engaging with the public was a key part of our project in order to ensure that the results of the project were of benefit and acceptable to all. In order to do this we carried out surveys with members of the public at strategic points to guide the project in the best direction.

First Survey

We carried out our first survey before Christmas to investigate the issues people would like to be addressed by an interdisciplinary science project. When combined with our teams skills this guided the overall direction of our project down the iGEM therapeutic track.

Do you think that synthetic biology can contribute towards the solution of serious global challenges?

All of our respondents thought that synthetic biology could contribute to serious global challenges which reassured us that the outcome of our synthetic biology project would be useful, and that this is an area of science that the public have faith in.

What area would you like a project of this sort to focus on?

We found that the majority of people questioned favoured medical treatments as their preferred area of research. This question was a free answer although the question prompted some answers: "For example: diagnostics, energy, environment, food and nutrition, information processing, manufacturing, therapeutics etc." This may have had an impact on what people chose, but out of the different iGEM tracks available medical and therapeutic purposes were the most preferred.

What specific problem would you like to have solved by an interdisciplinary, synthetic biology-based project?

This was a unprompted, free answer question and gave us answers such as Malaria, treatment of the common cold and asthma treatment. Many were quite vague and not feasible for us to solve in one summer, but one person suggested probiotic supplements which got us interested in using probiotics as a treatment for diseases in general.

Results

This survey was designed to give us some idea as to the direction our project should take. Based on this we decided to investigate the use of bacteria as a medical treatment.

Second Survey

In this survey we aimed to investigate the public’s awareness of scientific issues that arise from our project to establish the areas we need to focus on in our outreach activities, assess the level of support our project might have if it were to be used as a treatment in the future and to get an initial idea of whether people would prefer a single or repetaed treatment plan which effected the designs of our genetic circuit.

How old are you?

We found that we had an uneven spread of age groups among our respondents with a heavy bias towards under 21s. This is probably because the survey was shared via Facebook which has a lot of younger users, and shared particularly among our friends who we requested fill it in. In addition a lot of our friends aged under 21 are doing biology-related degrees at university so their knowledge may not be representative of their age group as a whole. We decided to split the results into under 21 and over 21 as the older groups were so sparsely populated there was little advantage in distinguishing between them.

Had you heard of genetic engineering before this survey?

We found that 90% people surveyed have heard of genetic engineering before this survey and we concluded that informing about genetic engineering shouldn't be our priority in our outreach activities.

Had you heard of synthetic biology before this questionnaire?

Only a small majority overall have heard of synthetic biology so we concluded it would be worth performing some outreach projects to make people more aware of synthetic biology so they can be more informed and engaged in our project. A majority of older people had not heard of synthetic biology before so ideally it this is the age group where we would be focussing our efforts. We concluded that we should target our outreach to more established forms of communication such as radio rather than focusing on just social media which has a much younger demographic.

Have you heard of Orphan Diseases (e.g. Wilson’s Disease)?

Our results showed that Orphan diseases need greater awareness as most people haven’t heard of them. When awareness of rare disease is low amongst both the public and medical professionals, patients of these diseases are less likely to get a correct diagnosis. Public awareness also affects the research allocation to rare diseases which are often underfunded.

If your doctor recommended the use of genetically engineered bacteria to treat an illness, would you use it?

Already a majority of people said they would use a genetically engineered bacteria as a treatment and a third of people didn’t know. If they were given more information about the treatment they might be persuaded to accept it so we should aim to do inform about the nature of our bacteria as we work on our project. Is the decision to take a treatment largely due to a doctor's recommendation or are other people making the decision for themselves from their own knowledge of synthetic biology? We found that a larger proportion of younger people prepared to take a probiotic treatment and previously a greater number of these people had heard of genetic engineering, suggesting this decision is linked to knowledge levels. this does not however account for the fact that attitudes to medical advice varies between age groups.

If you were given the option between taking a daily pill for an extended period of time, or a single probiotic bacterial pill to treat an illness, which would you choose?

A single pill is preferable to a daily pill for the majority of respondents, however our results show that most people would follow their doctor’s recommendation. This suggests in previous question that many of the responses in favour of such a treatment are in large part guided by the doctor's recommendation. We could do another survey to clarify this by repeating the question without giving them the option of allowing a doctor to choose for them. This question highlights how important it is to inform doctors not just patients of our treatment as their input would be required to make our treatment widely acceptable. We decided that we should discuss our treatment with doctors to get their opinions and work out what we would have to do to convince them that our probiotic is safe.

Results

In conclusion, the majority of people have heard of genetic engineering and synthetic biology. If we were to raise awareness of these issues then we should focus on older people rather than younger people, although there is benefit in talking to as many people as possible. Most people have not heard of orphan diseases so raising awareness of these should be a priority and we will try to do this. We found that people were wiling to follow what their doctors recommended so we should ensure that doctors are informed of our treatments, rather than just focusing on the view of patients. We should do another survey to clarify whether a single or daily dose is preferable, and maybe remove the reference to doctor's recommendation as this might be influencing people’s responses.

Third Survey

This survey was designed to investigate the ethical issues people might have with our project so we can respond to these and try and minimise these concerns through the design of project or generate counter arguments.

How old are you?

This time we had fewer responses than before and some groups have no people in them at all. Therefore we will split responses into under and over 21 like before. We think the reasons for this age spread are the same as those seen in survey 1 but older groups are even less represented in this survey because there are fewer responses overall.

Do you understand the term 'genetically-engineered bacteria'?

We covered this topic in the previous survey and received more responses in that. We will not analyse the data from this question therefore due to the smaller sample size.

If your doctor recommended the use of genetically-engineered bacteria to treat an illness, would you use it?

Again this question was better covered in the previous survey.

What do you think people's concerns are about the use of genetically-engineered bacteria (e.g., releasing genetically engineered bacteria into the environment, safety for the patient, "playing God", unjust or unnatural etc.)?

Issues related to safety (bottom four) were most important to people. We should combat this by focusing our research efforts on ways to stop our bacteria surviving outside the body and way to stop the treatment if it was having undesired affects. There were considered in our safety flowchart. Unknown long term effects are a concern to people so we should aim to minimise the use of risky techniques and educate people about the benefits this technology can provide in addition to allowing balanced discussion of the possible risks the technology could create. The same attitude applies for the concerns about God and unnatural methods. We should acknowledge that these are problems where people have legitimate fears and concerns and we should approach these concerns carefully and not dismiss them while bringing in a broader discussion on the potential benefits of synthetic biology.

The statements given as examples tended to be popular but we had no way of telling whether they would have been popular if unprompted – we should possibly have made this question a free, unprompted choice as we believe the question could still be understood without prompts. The number of responses for each point is dependent on how general the categories are, as we couldn't get the subtleties of individual answers onto a chart we had to group them together rather broadly to see which issues are the most pressing which involves making very subjective decisions in the interpretation of answers.

Why would you (or why do you think other people would) be against the use of these bacteria in a medical treatment?

Bacteria are perceived as pathogens so using them as a medical treatment seems counter-intuitive and people are not comfortable with willingly exposing themselves to bacteria. There is a sense that people are misinformed about GMOs and bacteria, so with more education both of these problems could be addressed. We will do this via our summer schools and social media presence. Unknown consequences and the lack of previous success are also issues. We could argue that we can only find the answers to these questions by investigating the treatment, or that the potential benefits of our project should outweigh the theoretical, unspecified disadvantages. There are still environmental and safety concerns, but the ethical and religious issues don’t seem to apply here, perhaps because this is specified as a medical treatment. If we think this is the case we should really emphasise the medical application of this technology, and specifically our project, if we want to ensure the widest support for what we’re doing.

Results

This survey shows us that we need to consider safety – all aspects of safety including environmental, patient and mutation risk safety. This is addressed in our safety flow chart. Unknown consequences should be considered, and although there will always be the possibility of these occurring we can take steps to minimise them and emphasise how the benefits of the treatment should outweigh them if implemented carefully. This is the same for unnatural and religious based arguments, we should acknowledge that these are potential issues and address them. However these views were not as widely held as we expected. To get people to be in favour of using bacteria as a medical treatment we will have to work hard to convince people that bacteria can be safe and useful rather than just a pathogen.

Fourth Survey

This survey was designed to investigate the preferred delivery methods for our treatment and the dosage frequency people would tolerate. This information was used to decide how to deliver our probiotic and to clarify whether people would prefer a permanent population in the small intestine or more frequent applications. This survey was performed in collaboration with iGEM Vilnius so that we can compare the results between the two different countries and see how opinions differ internationally.

Are you a Wilson's Disease patient?

We added this question about Wilson’s disease after we made the survey but before posting it on the Wilson’s Disease Support group Facebook page. We will assume that the people who didn’t answer this question do not have Wilson’s disease as the chance of someone with Wilson’s disease finding the survey and filling it in are very small. 21 respondents had Wilson’s disease, 16 respondents definitely did not and 40 respondents answered before we added this question but we assume they did not have Wilson’s disease either, making 56 overall. Vilnius did not ask this as they are working on phenylketonuria rather than Wilson’s disease.

Have you ever taken a probiotic treatment and, if so, did it have any effect?

In the UK the proportion of people who hadn’t tried a probiotic treatment was greater than those who had; in Lithuania the opposite is true. We believe these sort of treatments are more common in Lithuania that in the UK. Although we explained what a probiotic is this lack of familiarity may have stopped UK respondents recognising that this applies to food products. Of those who had tried a probiotic treatment, in all the large groups, more people said that they had no effect on their health than a positive effect, suggesting many people would be sceptical of using probiotics as a medical treatment. If the project were to be taken forward we would want to peform marketing to improve the image of probiotics so people would be more willing to take them.

In general, how would you prefer to take a probiotic treatment?

Consumable products are less popular in all groups than pharmaceutical products which suggests this is how we should plan to deliver our treatment. This is convenient because we can’t make food in our lab, controlling the dose is easier and people won’t get bored of having to take a certain type of food repeatedly and decline to take it. Pharmaceutical products may be more trusted or deemed more appropriate for treating a serious condition. Higher proportion of people in Lithuania would take the consumable product than the UK which we think is due to these sorts of products being more widespread in Lithuania. We discussed this with the team in Vilnius.

Of the options listed below, which would be your preferred pharmaceutical delivery method?

The UK results show that a gel-like bead or a tablet/pill are the most popular options. We decided to research a gel-like bead as this builds on work done by previous Oxford iGEM teams. Results from both countries show tablet or pill is the most popular but these are also the most familiar. It’s likely that people did’t really know what a gel-like bead would be meaning that we should inform them of this when explaining our project.

Would you prefer to take a probiotic treatment regularly or a single treatment that creates a permanent population of bacteria in the gut (meaning that no further treatment would be required)?

The majority of people want a single treatment so if this were feasible we should try to develop this. This could reduce the problems with storing the pills or beads as they would only need to be taken once so would not need to be stored in the home. We would need to ensure however that our bacteria could compete and survive in the human intestine otherwise a single treatment would be ineffective. We would need a control mechanism to kill the bacteria once they are outside the body regardless of whether it is a single or a regular treatment.

Ideally, how often would you prefer to take a probiotic treatment? (Select all that apply.)

Overall slightly more people would prefer to take the pill once a day than once ever, but Wilson’s patients are more likely to want a pill once ever than once a day. As these are people who know what it’s like to take a pill every day and would benefit most from our treatment this is another reason to develop a more long lasting treatment. This complements a question in the second survey we performed, in which we found that the majority of people who expressed a preference would prefer to take a single pill than a pill once a day.

If this were not possible, how often would you be prepared to take a probiotic treatment? (Select all that apply.)

A daily pill appears to be acceptable to most people, so if we were unable to make a sustainable probiotic population, this would be an alternative we should investigate. People would be prepared to take it more than once a day if necessary so we if we found that the amount of bacteria we need to turnover is too high to take just once a day, our probiotic would still be acceptable if taken more frequently. Ideally we would like to create a population with some ability to persist so that our treatment is improved, at least in regards to dosage frequency, over the existing treatments for Wilson’s disease which have to be taken multiple times a day.

Results

From this survey we have found that probiotic treatments are not widely taken in the UK but results from Lithuania suggest they may be more common in other countries. We might need to raise more awareness of them if we were to develop this into an actual product rather than a proof of concept. We should investigate a pharmaceutical delivery method rather than a consumable product delivery method. We decided to investigate delivery via a gel-like bead because this was one of the most popular options in the UK and it is feasible for us to achieve. A single treatment is more popular than a regular treatment. If we were to re-run this survey in the future we should prevent people from giving more than one answer as this makes the results very hard to interpret. If necessary people would be willing take a pill once a day, so if we find we couldn't make a population that persist in the small intestine, our probiotic may still have value.